Evidence map›Paper›PMID 22452947›Full record

ArticleMolecular cancer therapeutics2012

Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide induction.

Marisa Meyers-Needham, Jocelyn A Lewis, Salih Gencer, R David Sentelle, Sahar A Saddoughi, Christopher J Clarke, Yusuf A Hannun, Haakan Norell, Telma Martins da Palma, Michael Nishimura and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Hedgehog Signaling Pathway Orchestrates Human Lung Branching Morphogenesis.International journal of molecular sciences · 2022
    Article
  4. Review
  5. Article
  6. Review
  7. Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Marisa Meyers-NeedhamDepartment of Biochemistry and Molecular Biology, Medical University of South Carolina, Charleston, SC 29425, USA.
Jocelyn A Lewis
Salih Gencer
R David Sentelle
Sahar A Saddoughi
Christopher J Clarke
Yusuf A Hannun
Haakan Norell
Telma Martins da Palma
Michael Nishimura
Jacqueline M Kraveka
Zohreh Khavandgar
Monzur Murshed
M Ozgur Cevik
Besim Ogretmen
MUSC Hollings Cancer Center · USMcGill University · CAMedical University of South Carolina · US

Funding

Ceramide Signaling in the Regulation of Head & Neck Cancer Cell Death and TherapyR01DE016572 · NIDCR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI OGRETMEN, BESIM · 2005 to 2025
$7.4M
Regulation of Telomerase by Sphingolipid Signaling in Lung CancerR01CA088932 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI OGRETMEN, BESIM · 2002 to 2017
$3.3M
MUSC FACIL EXPANSION &RENOV: SLE C06RR015455 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI CROUCH, ROSALIE K · 2002 to 2002
$2.0M
NCI NIH HHS CA088932NCI NIH HHS CA097165NCI NIH HHS R01 CA088932NCRR NIH HHS C06 RR015455NIDCR NIH HHS DE016572NIDCR NIH HHS R01 DE016572
6 · The paper itself

Abstract

Sonic hedgehog (SHh) signaling is important in the pathogenesis of various human cancers, such as medulloblastomas, and it has been identified as a valid target for anticancer therapeutics. The SHh inhibitor cyclopamine induces apoptosis. The bioactive sphingolipid ceramide mediates cell death in response to various chemotherapeutic agents; however, ceramide's roles/mechanisms in cyclopamine-induced apoptosis are unknown. Here, we report that cyclopamine mediates ceramide generation selectively via induction of neutral sphingomyelin phosphodiesterase 3, SMPD3 (nSMase2) in Daoy human medulloblastoma cells. Importantly, short interfering RNA-mediated knockdown of nSMase2 prevented cyclopamine-induced ceramide generation and protected Daoy cells from drug-induced apoptosis. Accordingly, ectopic wild-type N-SMase2 caused cell death, compared with controls, which express the catalytically inactive N-SMase2 mutant. Interestingly, knockdown of smoothened (Smo), a target protein for cyclopamine, or Gli1, a downstream signaling transcription factor of Smo, did not affect nSMase2. Mechanistically, our data showed that cyclopamine induced nSMase2 and cell death selectively via increased nitric oxide (NO) generation by neuronal-nitric oxide synthase (n-NOS) induction, in Daoy medulloblastoma, and multiple other human cancer cell lines. Knockdown of n-NOS prevented nSMase2 induction and cell death in response to cyclopamine. Accordingly, N-SMase2 activity-deficient skin fibroblasts isolated from homozygous fro/fro (fragilitas ossium) mice exhibited resistance to NO-induced cell death. Thus, our data suggest a novel off-target function of cyclopamine in inducing apoptosis, at least in part, by n-NOS/NO-dependent induction of N-SMase2/ceramide axis, independent of Smo/Gli inhibition.

Indexed as

AnimalsApoptosisCell Line, TumorCeramidesDown-RegulationEnzyme ActivationHedgehog ProteinsHumansMiceNitric OxideOxidative StressReceptors, G-Protein-CoupledSmoothened ReceptorSphingomyelin PhosphodiesteraseVeratrum AlkaloidsCeramidescyclopamineHedgehog ProteinsNitric OxideReceptors, G-Protein-CoupledSmoothened ReceptorSMO protein, humanSMPD3 protein, humanSphingomyelin PhosphodiesteraseVeratrum Alkaloids

Identifiers

PMID22452947
PMCPMC3709261
OpenAlexW2099259281

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.